A. Fanjul

发表

From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer

Robert H. Bell, F. Hormozdiari, Faraz Hach, 2012, The Journal of pathology.

CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice

A. Fanjul, K. Ley, J. Olefsky, 2018, Molecular metabolism.

A new class of retinoids with selective inhibition of AP-1 inhibits proliferation

A. Fanjul, M. Pfahl, M. Dawson, 1994, Nature.

Retinoic acid receptors and retinoid X receptor-alpha down-regulate the transforming growth factor-beta 1 promoter by antagonizing AP-1 activity.

A. Fanjul, M. Pfahl, Seong-Jin Kim, 1993, Molecular endocrinology.

Retinoids selective for retinoid X receptor response pathways.

J. Lehmann, A. Fanjul, P. Haefner, 1992, Science.

Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function

Jong Bae Seo, A. Fanjul, J. Olefsky, 2018, The Journal of clinical investigation.

Demonstration of Proof of Mechanism and Pharmacokinetics and Pharmacodynamic Relationship with 4′-Cyano-biphenyl-4-sulfonic Acid (6-Amino-pyridin-2-yl)-amide (PF-915275), an Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1, in Cynomolgus Monkeys

A. Fanjul, P. Rejto, P. Stewart, 2008, Journal of Pharmacology and Experimental Therapeutics.

4-Hydroxyphenyl Retinamide Is a Highly Selective Activator of Retinoid Receptors*

A. Fanjul, M. Pfahl, M. Pierotti, 1996, The Journal of Biological Chemistry.

A selective retinoid with high activity against an androgen‐resistant prostate cancer cell type

N. Picard, A. Fanjul, M. Pfahl, 1999, International journal of cancer.

Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding

Zhou Zhu, A. Fanjul, P. Rejto, 2012, BMC Genomics.

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes

A. Fanjul, P. Farrell, J. Bilakovics, 2019, The Journal of Biological Chemistry.

The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors.

A. Fanjul, P. Rejto, G. Paderes, 2010, Bioorganic & medicinal chemistry letters.

Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.

A. Fanjul, M. Pairish, Liming Dong, 2012, Bioorganic & medicinal chemistry letters.

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors

A. Fanjul, C. Zopf, Christopher Mcbride, 2019, The Journal of Pharmacology and Experimental Therapeutics.

University of Birmingham A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis

A. Fanjul, P. Rejto, C. Darimont, 2008 .

Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons.

A. Fanjul, M. Pfahl, M. Dawson, 1996, Cancer research.

A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo

M. Gleave, A. Zoubeidi, A. Fanjul, 2013, Molecular Cancer Therapeutics.

Novel retinoid-related molecules as apoptosis inducers and effectve inhibitors of human lung cancer cells in vivo

N. Picard, A. Fanjul, M. Pfahl, 1997, Nature Medicine.

Human induced pluripotent stem cell‐derived macrophages ameliorate liver fibrosis

P. Tamayo, A. Fanjul, D. Kaufman, 2021, Stem cells.

Nuclear retinoid receptors and their mechanism of action.

A. Fanjul, M. Pfahl, G. Salbert, 1994, Vitamins and hormones.

Genome-wide CRISPR Screening to Identify Drivers of TGF-β-Induced Liver Fibrosis in Human Hepatic Stellate Cells

A. Fanjul, Erin N. Smith, D. Erion, 2022, ACS chemical biology.

Dopamine and ghrelin receptor co‐expression and interaction in the spinal defecation centers

A. Fanjul, J. Furness, A. Syder, 2020, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.

A. Fanjul, M. Pairish, S. Greasley, 2012, Bioorganic & medicinal chemistry letters.

Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.

M. Gleave, A. Zoubeidi, A. Fanjul, 2011, Journal of medicinal chemistry.

Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist.

A. Fanjul, M. Pfahl, F. J. Piedrafita, 1998, Cancer research.

A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis

P M Stewart, A. Fanjul, P. Rejto, 2008, The Journal of endocrinology.

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolites.

A. Fanjul, P. Rejto, M. Edwards, 2013, Bioorganic & medicinal chemistry letters.

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275.

A. Fanjul, M. Edwards, J. Ermolieff, 2009, Bioorganic & medicinal chemistry letters.

Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.

A. Fanjul, Petro Halkowycz, D. Dougan, 2017, Bioorganic & medicinal chemistry letters.